EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms

Thomas Systchenko iD, Jean-Claude Chomel iD, Pilar Gallego-Hernanz iD, Niels Moya, Déborah Desmier, Natacha Maillard, Arthur Bobin, Mathilde Vonfeld, Hélène Gardeney, Emilie Cayssials E iD, José Torregrosa

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Thomas Systchenko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Haematology Department, CHU de Poitiers, Poitiers, France. Hauptthemen laut MEDLINE: Azacitidine, Myeloproliferative Disorders. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms in blastic phase (MPN‐BP) have a dreadful prognosis. We report the characteristics and outcomes of five MPN‐BP patients treated with a never‐before‐described combination of azacytidine and venetoclax (to control BP transformation), added to ruxolitinib (needed to control constitutional symptoms). Median age was 76 years (range 72–84), and worst performance status was 2. The overall response rate was 80%, and the complete remission rate was 40%. With median follow‐up of 10.0 months (range 4.2–13.4), median overall survival was 13.4 months (95% CI 4.2–13.4). We did not detect any unexpected treatment‐related toxicity, and quality of life was improved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzacitidineMyeloproliferative DisordersHumansAgedAged, 80 and overBlast CrisisTreatment OutcomeQuality of LifeNitrilesPyrazolesPyrimidinesSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

azacitidineblast phase myeloproliferative neoplasmsruxolitinibvenetoclax

Substanzen

AzacitidineruxolitinibNitrilesPyrazolesPyrimidinesvenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Haematology Department, CHU de Poitiers, Poitiers, France.
  • Department of Cancer Biology, Onco-Hematology Unit, CHU de Poitiers, Poitiers, France.

ORCID-Profile: Thomas Systchenko, Jean-Claude Chomel, Pilar Gallego-Hernanz, Emilie Cayssials E

Zitieren

APA

Systchenko, T., Chomel, J. C., Gallego-Hernanz, P., Moya, N., Desmier, D., Maillard, N., Bobin, A., Vonfeld, M., Gardeney, H., Cayssials E, E., & Torregrosa, J. (2023). Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms. British Journal of Haematology. https://doi.org/10.1111/bjh.18853

Vancouver

Systchenko T, Chomel JC, Gallego-Hernanz P, Moya N, Desmier D, Maillard N, et al. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms. British Journal of Haematology. 2023. doi:10.1111/bjh.18853

BibTeX
@article{Systchenko2023,
  author = {Systchenko, Thomas and Chomel, Jean-Claude and Gallego-Hernanz, Pilar and Moya, Niels and Desmier, Déborah and Maillard, Natacha and Bobin, Arthur and Vonfeld, Mathilde and Gardeney, Hélène and Cayssials E, Emilie and Torregrosa, José},
  title = {Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18853}
}
Kostenlos starten →